Abstract: Objective  To summarize the preliminary clinical application results of FLIXENE™ (Atrium™, Hudson, NH, USA), an early cannulation artificial vascular graft.  Methods  A total of 48 cases subjected to arteriovenous graft construction using the early cannulation FLIXENE™ vascular graft at the Department of Vascular Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from August 2019 to October 2021 were retrospectively analyzed. The first cannulation time, patency rate and incidence of complications were summarized.  Results   There were 18 males and 30 females, with an average age of 60.06±11.93 years. The arteriovenous graft was established in upper limbs (n=40) or in lower limbs (n=8), with the clinical success rate of 100% and without any perioperative complications. The first cannulation time after operation was 15～336h, with the median time of 20 (18, 22) h. The average follow-up time was 224.77±151.73 days, and the follow-up rate was 100%. Complications included thrombus (2 cases), stenosis (9 cases) and infection (2 cases). No hematoma at puncture site, seroma, pseudoaneurysm, or steal syndrome occurred. After the operation for 3, 6 and 12 months, the primary patency rates were 95.3%, 87.4% and 63.0%, respectively, the primary assisted patency rates were 100%, 97.4%, and 92.2% respectively, and the secondary patency rates were 100%.  Conclusions  The early cannulation FLIXENE™ vascular graft is safe and feasible for early cannulation hemodialysis. 

Key words: Hemodialysis access, Early cannulation graft, Arteriovenous graft